The association of GPR85 with PSD-95-neuroligin complex and autism spectrum disorder: a molecular analysis by Eriko Fujita-Jimbo et al.
Fujita-Jimbo et al. Molecular Autism  (2015) 6:17 
DOI 10.1186/s13229-015-0012-5RESEARCH Open AccessThe association of GPR85 with PSD-95-neuroligin
complex and autism spectrum disorder: a
molecular analysis
Eriko Fujita-Jimbo1,2†, Yuko Tanabe2†, Zhiling Yu1,3†, Karin Kojima1, Masato Mori1, Hong Li1,4, Sadahiko Iwamoto5,
Takanori Yamagata1, Mariko Y Momoi1,2* and Takashi Momoi2*Abstract
Background: Autism spectrum disorder (ASD) has a complex genetic etiology. Some symptoms and mutated
genes, including neuroligin (NLGN), neurexin (NRXN), and SH3 and multiple ankyrin repeat domains protein
(SHANK), are shared by schizophrenia and ASD. Little is known about the molecular pathogenesis of ASD. One
of the possible molecular pathogenesis is an imbalance of excitatory and inhibitory receptors linked with the
NLGN-PSD-95-SHANK complex via postsynaptic density protein/Drosophila disc large tumor suppressor/zonula
occludens-1 protein (PDZ) binding. In the present study, we focused on GPR85 as a candidate gene for ASD
because the C-terminal amino acid sequence of GPR85 [Thr-Cys-Val-Ile (YCVI)] is classified as a type II PDZ-binding
motif, and GPR85 is a risk factor for schizophrenia. GPR85 is an orphan receptor that regulates neural and synaptic
plasticity and modulates diverse behaviors, including learning and memory. While searching for molecules that
associate with GPR85, we found that GPR85 was associated with postsynaptic density protein (PSD)-95 linked with
NLGN in the brain.
Methods: We examined the proteins that associate with the C-terminal sequence of GPR85 by pull-down assay and
immunoblot analysis and searched for a mutation of the GPR85 gene in patients with ASD. We used immunostaining
to examine the intracellular localization of mutated GPR85 and its influence on the morphology of cells and neurons.
Results: The C-terminal sequence of GPR85 interacted with PSD-95 at PDZ1, while NLGN interacted with PSD-95 at
PDZ3. Two male patients with ASD from independent Japanese families possessed inherited missense mutations at
conserved sites in GPR85: one had T1033C (M152T) and the other had G1239T (V221L). These mutations were located
in a domain related to G protein interaction and signal transduction. In contrast to wild-type GPR85, mutated GPR85
was more preferentially accumulated, causing endoplasmic reticulum stress, and disturbed the dendrite formation of
hippocampal neurons.
Conclusions: GPR85 associated with the PSD-95 linked with NLGN, which is related to ASD. GPR85 carrying the
mutations detected in ASD patients disturbed dendrite formation that could be the candidate for molecular
pathogenesis of ASD through the associated NLGN-PSD-95 receptor complex.
Keywords: Autism spectrum disorder, ASD, GPCR, ER stress, Synaptic receptors, GPR85* Correspondence: mymomoi@iuhw.ac.jp; momoi@iuhw.ac.jp
†Equal contributors
1Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji,
Shimotsuke-shi, Tochigi 3290498, Japan
2Medical Research Center, International University of Welfare and Health,
2600-1 Kitakanemaru, Ohtawara 3248501, Japan
Full list of author information is available at the end of the article
© 2015 Fujita-Jimbo et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Fujita-Jimbo et al. Molecular Autism  (2015) 6:17 Page 2 of 10Background
Autism spectrum disorder (ASD) has a complex genetic
etiology. Of the genes that have been shown to confer
susceptibility to ASD, many are involved in synaptic ad-
hesion and formation, including neuroligins (NLGN) 3
and 4 [1], SH3 and multiple ankyrin repeat domains pro-
tein (SHANK) 3 [2], contactin-associated protein-like
(CNTNAP) 2 [3], and cell adhesion molecule (CADM) 1
[4]. For instance, NLGNs are postsynaptic cell adhesion
proteins that interact with neurexins (NRXN) on the
presynaptic membrane, and they are required for syn-
apse maturation [5]. NRXN-NLGN interactions induce
differentiation of γ-aminobutyric acid (GABA) and glu-
tamate postsynaptic specializations [5]. The extracellular
domain of NLGN displays trans-cell adhesion activity [6],
and its intracellular domain of NLGN associates with
postsynaptic density protein (PSD)-95 via individual post-
synaptic density protein/Drosophila disc large tumor sup-
pressor/zonula occludens-1 protein (PDZ) domains [7].
One of possible causes of pathogenesis is an imbalance of
receptors including excitatory and inhibitory receptors
linked with the NLGN-PSD-95-SHANK complex via PDZ
binding [5].
In addition to synaptic adhesion molecules, alterations in
G-protein-coupled receptor (GPCR; GPR) signaling are
likely to be associated with ASD pathogenesis. GPRs
include the GABA and serotonin [5-hydroxytryptamine (5-
HT)] receptors - which are involved in numerous neuronal
processes, including the regulation of synaptic formation
and transduction [8]. We recently found that mutations in
the GPR37 gene, located in the ASD linkage locus 9
(AUTS9) on chromosome 7q31, are associated with the
manifestation of ASD [9]. Some mutations apparently had
a causative, deleterious effect, and other mutations ap-
peared to confer susceptibility to ASD under predisposing
conditions [9].
Mutations in NRXN1, NRXN2, NLGN2, NLGN4, and
SHANK3 genes related to ASD have been also found in
schizophrenia patients [10-13]. There are some over-
lapping symptoms between schizophrenia and autism,
particularly the negative symptoms (poverty of speech
and volition, social withdrawal, and blunt affect) [14,15].
Pharmacological treatments have also suggested that
GPRs are the common target molecules in psychiatric dis-
orders including ASD and schizophrenia [14]. Thus, the
pathogenesis of ASD and schizophrenia may have some
common molecular basis [15], but little is known about
them. We focused on GPR85 located in the AUTS9 locus
in the 7q31 region [16] that harbors GPR37 [17].
GPR85 is involved in predisposing patients to a high risk
of schizophrenia; two GPR85 SNPs in moderate linkage
disequilibrium have been associated with schizophrenia
[18], but mutations in GPR85 have not been found in
patients with schizophrenia. GPR85 is an orphan receptorthat is involved in determining brain size, regulating
neural and synaptic plasticity, and modulating diverse be-
haviors (including learning and memory) [18]. The amino
acid sequence of GPR85 is identical in all vertebrates
[19,20]. GPR85 has type II PDZ-binding motif, Thr-Cys-
Val-Ile (YCVI), at its C-terminal region [21]. During the
study on the common molecular basis in the psychiatric
disorders including schizophrenia and ASD, we found that
the C-terminal sequence of GPR85 was linked with NLGN
and PDZ proteins including PSD-95 in the brain.
In the present study, we examined the interaction be-
tween GPR85 and PDZ proteins linked with NLGN and
mutations of GPR85 in ASD patients. Here, we show
two independent missense mutations in the GPR85
gene of Japanese patients with ASD and describe the
mutated GPR85-induced endoplasmic reticulum (ER)
stress and deleterious effect on the dendrite formation
of neurons.
Methods
Participants
Lymphocytes were obtained from 72 unrelated Japanese
ASD patients with autism or a pervasive developmental
disorder not otherwise specified. Their conditions were
diagnosed according to criteria outlined in the Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV). Written informed consent was ob-
tained from the parents of all patients. The patients in-
cluded 57 males and 15 females, aged 3 to 23 years, with
intellectual levels that varied from normal to severely dis-
abled. Four probands had siblings with ASD, and others
were sporadic. Control (N = 622) samples, including male
(N = 381) and female (N = 241) samples, were obtained
from healthy Japanese adult volunteers after they provided
written, informed consent. We also obtained the DNA of
200 Caucasian patients from the Autism Genetic Resource
Exchange Consortium (Cure Autism Now, Los Angeles,
CA). AGRE samples included 172 males and 28 females;
all were familial cases. Caucasian control DNA samples
were obtained from the Coriell Institute (Camden, NJ).
Written informed consent was obtained from the par-
ents of all subjects, subjects themselves in capable cases,
and control subjects. The study was approved by the
Bioethics Committee for Human Gene Analysis of Jichi
Medical University (approval number, 11–52, 12–87).
Direct sequencing analysis
Genomic DNA was extracted from peripheral blood lym-
phocytes or lymphoblasts using a standard method de-
scribed by the manufacturer. We used polymerase chain
reaction (PCR) primers to amplify each exon and its
boundaries in the GPR85 regions. The primers are listed
in Additional file 1: Table S1. PCR products were purified
by passing them through micro-concentrating centrifugal
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reactions were performed using the Applied Biosystems
Dye-Terminator Kit and analyzed on an ABI Prism
3730 DNA Sequencer (Applied Biosystems, Foster City,
CA, USA).Site-directed mutagenesis and DNA construction
The full length of GPR85 cDNA was isolated from human
cDNA library (Stratagene, La Jolla, CA, USA). To generate
GPR85 mutants, site-directed mutagenesis were per-
formed by using QuikChange II Site-Directed Mutagen-
esis kit (Stratagene) with the following primers: for
mutation of M152T, sense primer: 5′-CTCTGTCTGTGG
CCACGGCATTTCCCCCGGTTTT-3′; antisense primer:
5′-AAAACCGGGGGAAATGCCGTGGCCACAGACAG
AG-3′; for mutation of V221L, sense primer: 5′-GAAG
CCAGTCCAGTTTTTAGCAGCAGTCAGCCA-3′; anti-
sense primer: 5′-TGGCTGACTGCTGCTAAAAACTGG
ACTGGCTTC-3′. Underlined nucleotides were mutated
sites. Mutations were confirmed by DNA sequencing.
The enzyme-digested PCR DNA fragments corre-
sponding to full-length GPR85 and full-length GPR85-
deltaC for the pcDNA4/TO/myc-His expression vector
(Invitrogen, Carlsbad, CA, USA) or pcDEF3-FLAG vec-
tor [4], GPR85-C and GPR85-deltaC were subcloned
into pGEM-T easy vector (Promega, Madison, WI, USA)
using GPR85 PCR primers as follows: forward primer:
5′-GGTACCATGGCGAACTATAGCCATGC-3′ for full-
length GPR85 and full-length GPR85-deltaC, and reverse
primer: 5′-GGTACCGTATAACACAGTAAGGTTCC-3′
for full-length GPR85-myc-His; or reverse primer: 5′-
GGTACCGAGGTTCCTTGGTAAC-3′ for full-length
GPR85-deltaC-myc-His, reverse primer: 5-GAATTCTCA
TATAACACAGTAAGGTTCC-3 for FLAG-full-length
GPR85; or reverse primer: 5-GAATTCTCAAGGTTCC
TTGGTAAC-3 for FLAG-full-length GPR85-deltaC, for-
ward primer: 5′-GGATCCTCCAGGTTACCAAGGGAA
CC-3′ for GPR85-C and GPR85-deltaC, and reverse pri-
mer: 5′-GGATCCTCATATAACACAGTAAGGTTC-3′
for GPR85-C; or reverse primer: 5′-GGATCCTCAAGG
TTCCTTGGTAAC-3′ for GPR85-deltaC. Full-length
GPR85 and GPR85-deltaC were subcloned into Kpn1
sites of the pcDNA4/TO/myc-His expression vector,
and GPR85-C and GPR85-deltaC fragments were sub-
cloned into BamH1 sites pGEX4T-3 vector (Pharmacia,
Buckinghamshire, UK). FLAG-GPR85 wild type and
mutants in pGEM-T easy vector were subcloned into
EcoR1 sites pcDEF3-FLAG vector.
The experiments were approved by the Genetic Modi-
fication Safety Committee of Jichi University (approval
number, 11–52) and were carried out under the jurisdic-
tion of the Ministry of Education, Culture, Sports, Sci-
ence and Technology.Animal care
We followed the Fundamental Guidelines for Proper
Conduct of Animal Experiments and Related Activities
in Academic Research Institutions under the jurisdiction
of the Ministry of Education, Culture, Sports, Science
and Technology. All protocols for animal handling and
treatment were reviewed and approved by the Animal
Care and Use Committee of Jichi University (approval
numbers, 11-157, 12076) and by the International Uni-
versity of Health and Welfare (approval numbers,
D1008, 10118).
Cell culture
Primary culture of hippocampal neurons was prepared
from mouse wild-type embryos at embryonic day (E) 18
as previously described [22]. Neurones maintained in
AraC (5 μM)-containing medium for 2 days (days in vitro
(DIV) 3 to 5). Briefly, hippocampalis were dissected in
Hepes-buffered saline solution and dissociated by adding
10% trypsin and 1% DNase and incubating for 15 min.
Neurons were plated at a density of 2 × 104 cells/cm2 on
0.05% polyethylenimine-treated, 1.2 mm-diameter cover
slips (Matsunami, Osaka, Japan) and incubated in Neu-
robasal™ medium with B-27 supplement (Invitrogen) and
2% fetal bovine serum. Cultures were maintained at 37°C
in 5% CO2. Half of the growth medium was exchanged
with fresh medium once a week. Neurons with developed
dendritic arbors were used for the experiments. COS and
C2C5 [23] cells were cultured in α-minimum essential
medium (MEM) with 10% fetal bovine serum (FBS) at
37 °C in a humidified atmosphere of 5% CO2.
Transfection
Neurons (cultured for 7 days (DIV 7)) and C2C5 cells
were transfected with pcDNA4 plasmid containing wild-
type or mutated GPR85 (M152T or V221L)-myc-his,
pcDEF plasmid containing FLAG-wild-type, mutated
GPR85 (M152T or V221L), or wild-type, mutated GPR85
(M152T or V221L)-deltaC and PSD-95-GFP [24] con-
structs. Transfections were performed with lipofectamine
2000, and then cells were incubated for 28 to 48 h.
Immunoblot analysis
C2C5 cells were lysed in buffer (20 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-
100) and protease inhibitor or buffer A in ProteoExtract®
Native Membrane Protein Extraction Kit according to
the manufacturer’s protocol (Merck Millipore, Darm-
stadt, Germany). Separated proteins were transferred to
nitrocellulose transfer membrane by electroblotting.
Nonspecific binding was blocked with 0.5% nonfat dry
milk with 0.1% Triton X-100 in PBS. After centrifuga-
tion, 40 μg of total protein was subjected to SDS-PAGE
(7.5% to 12%). Then, blots were incubated overnight at
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anti-CHOP (Santa Cruz Biotech. Inc., Dallas, Texas, USA)
levels were assessed by adding alkaline phosphatase-
conjugated and goat anti-rabbit or anti-mouse immuno-
globulins (Promega) and detecting the signals generated
in reactions with nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolyl-1-phosphate. Data from three experi-
ments were scanned and analyzed for quantification with
Image J software (National Institutes of Health). Results
compared with wild type were analyzed using Student’s
t-test (P < 0.05 was considered statistically significant).
Immunostaining
Cells were fixed in 4% paraformaldehyde (PFA) or metha-
nol in PBS. After they were incubated with blocking re-
agent (PBS containing 1% goat serum, 1% skim milk, and
0.1% Triton X-100) for 1 h at room temperature, they
were then subjected to the immunostaining using mouse
anti-His, rabbit anti-His (MBL, Nagoya, Japan), mouse
anti-FLAG, rabbit anti-FLAG (Sigma), rabbit anti-eIF2α
(Cell Signaling Technology, Inc., Danvers, MA, USA),
mouse anti-CHOP (Santa Cruz Biotechnology), mouse
anti-MAP2 (Sigma), mouse anti-PSD-95 (Thermo Fisher
Scientific, Rockford, IL, USA), and rabbit caspase-3 [25].
Alexa-Fluor-488- and Alexa-Fluor-568-conjugated sec-
ondary antibodies against mouse and rabbit IgG were pur-
chased from Molecular Probes (Eugene, OR, USA). Nuclei
were detected by Hoechst 33342 (Molecular Probes).
Immunofluorescence was viewed using a confocal laser-
scanning microscope (CSU-10, Yokogawa Electric Co.,
Tokyo, Japan), a Leica TCS SP5 confocal microscope, and
Leica AF6000 Modular Systems (Leica Microsystems,
Wetzlar, Germany).
The percentages of C2C5 cells that showed apoptotic
morphology and CHOP, P-eIF2, and caspase-3 positivity
were determined from a total of 200 cells that expressed
wild type or 200 cells that expressed mutant GPR85 at
28 to 48 h after transfection. The percentage neurons
with long dendrites were determined from a total of 100
neurons that expressed wild type or 100 neurons that
expressed mutant GPR85 at 28 to 48 h after transfection.
The experiments were repeated three times. The values
represent averages of the percentages of the number of
cells obtained in three experiments. Results were ana-
lyzed using Student’s t-tests (*P < 0.05 **P < 0.01 was
considered statistically significant).
GST pull-down assay
For in vitro pull-down assays, glutathione S-transferase
(GST; estimated MW; 26 kDa) and the GST fusion proteins
GST-GPR85-C including amino acids (SRLPREPYCVI)
(estimated MW; 27.5 kDa) and GST-GPR85-deltaC (lack-
ing the PDZ-binding sequence, YCVI) (estimated MW;
27.1 kDa) were purified by Glutathione Sepharose 4B (GEHealthcare Biosciences, Buckinghamshire, UK) from the
extract of Escherichia coli containing each plasmid. GST fu-
sion proteins bound to Sepharose beads were incubated
with lysates from the brain or COS cells transfected with
GFP-PSD-95 and GFP-SAP102 for 2 h at 4°C. The beads
were washed three times with lysis buffer and then eluted
with 50 mM Tris-HCl (pH 8.0) containing 20 mM reduced
glutathione. The bound proteins were then separated by
SDS-PAGE and detected by immunoblotting using the
following primary antibodies: rabbit anti-SAP102 (Synaptic
systems, Goettingen, Germany), rabbit anti-PSD-95
(Millipore), mouse anti-Mupp1 (Becton Dickinson,
Franklin Lakes, NJ, USA), mouse anti-Neuroligin
(Synaptic Systems), mouse anti-GFP (Roche Diagnostics
Schweiz, Rotkreuz, Switzerland), and rabbit anti-GST
(Santa Cruz Biotechnology).
Results
The C-terminal amino acid sequence of human and
mouse GPR85 (YCVI) is classified as a type II PDZ-
binding motif [21]. We employed a pull-down assay and
immunoblot analysis using specific antibodies to examine
whether the C-terminal sequence of GPR85 (GPR85-C)
interacts with PDZ proteins in the mouse brain. In mouse
brain extracts, GPR85-C interacted with PSD-95, SAP102,
and NLGN, but not with Mupp1 (Figure 1a). As NLGN
binds PSD-95 and SAP102 through its C-terminal PDZ-
binding domain, we examined the interaction between
GPR85-C and GFP-PSD-95 or GFP-SAP102 expressed in
COS cells using pull-down assay and immunoblotting
with anti-GFP (Figure 1b). GPR85-C interacted more
strongly with GFP-PSD-95 than with GFP-SAP102.
Next, we examined the binding domain in detail during
the interaction between GPR85 and PSD-95 (Figure 2).
GPR85-C lacking YCVI (GPR85-deltaC) did not interact
with PSD-95 (Figure 2a). PSD-95 has three PDZ domains,
PDZ1, PDZ2, and PDZ3. GPR85-C interacted with PDZ1,
but not with PDZ2 or PDZ3 (Figure 2b). Therefore,
GPR85 likely associated with the NLGN-PSD-95 complex
related to pathogenesis of ASD through individual PDZ
domains.
To examine the common molecular basis of schizo-
phrenia and ASD, we searched for GPR85 mutations
in Caucasian and Japanese ASD patients. In two males
among 72 Japanese patients, we identified two base
alterations in GPR85 that caused amino acid substitu-
tions: one was T1033C (M152T) and the other G1239T
(V221L) (Table 1; Figure 3a, b). Each of these mutations
was also detected in the patients’ apparently unaffected
mothers (Figure 3a, b). No sample was available to test
the brother of the patient with V221L. Neither base al-
teration was found in 189 Caucasian ASD samples and
622 healthy Japanese volunteers. Individuals with either
the M152T or V221L mutation in GPR85 presented with
Figure 2 Identification of PDZ domain of PSD-95 interacting
with GPR85-C. (a) PSD-95 was associated with GST-GPR85-C, but
not with GST-GPR85-deltaC lacking YCVI. (b) GST-GPR85-C interacted
with PDZ1 of PSD-95, but not with PDZ2 nor PDZ3. GST, glutathione
S-transferase; PDZ, postsynaptic density protein/Drosophila disc large
tumor suppressor/zonula occludens-1 protein; PSD, postsynaptic
density protein.
Figure 1 Pull-down and immunoblot analysis for the proteins
associating with GPR85-C. (a) GPR85-C-associating proteins in the
mouse brain. The extracts from the mouse brains were subjected to
the pull-down assay using GST-GPR85-C and immunoblot analysis.
GPR85-C band with PSD-95, SAP102, and NLGN, but not with Mupp1
in the extracts from mouse brain. (b) The interaction between GPR85-C
and PSD-95 or SAP102. The extracts from COS cells transfected with
GFP-PSD-95, GFP-SAP102, and GFP-Mupp-1 were subjected to the
pull-down assay using GST-GPR85-C. GPR85-C interacted with GFP-
PSD-95 and weakly interacted with GFP-SAP102, but not with Mupp1.
GST, glutathione S-transferase; PSD, postsynaptic density protein.
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mild intellectual disability, the ability to speak some sim-
ple words, and no epilepsy. We also detected two single
base substitutions (Table 1), but they were different from
the SNPs (rs56080411 and rs56039557) reported as risk
factors of schizophrenia [18].
GPR85 is transcribed into four RNA isoforms that, like
other GPCRs, encode seven transmembrane (TM) do-
mains. These four GPR85 RNA isoforms are registered in
GenBank as NM_001146265.1, NM_018970.6, NM_001
146266.1, and NM_001146267.1. The two mutations
found in this study, M152T and V221L, were located in
exon 3, which is present in all four RNA isoforms. One
mutation was located in the fourth TM domain and the
other in the cytoplasmic region adjacent to the fifth TM
domain (Figure 3c).
We focused on the intracellular localization of the
wild-type and mutated GPR85 proteins expressed in
C2C5 cells. Both the exogenous and endogenous GPR85
proteins were localized mainly in the ER [see Additional
file 2: Figure S1]. Compared to wild-type GPR85, GPR85
Table 1 Results of the analysis of GPR85
Base change AA change Patients Control Report
Japanese
patients
(n = 72)
c.830C > T p.G84G (C/C) 71/72 SNP
(C/T) 1/72
(T/T) 0/72
c.938 C > T p.Y120Y (C/C) 71/72 SNP
(T/C) 1/72
(T/T) 0/72
c.1033 T > C p.M152T (T/C) 1/72 0/622 Fa-, Mo+
c.1239G > T p.V221L (G/T) 1/72 0/622 Fa-, Mo+, Bro
NA
Caucasian
patients
(n = 189)
c.830C > T p.G84G (C/C) 111/151 SNP
(C/T) 37/151
(T/T) 3/151
c.938C > T p.Y120Y (C/C) 139/187 SNP
(T/C) 44/187
(T/T) 4/187
Figure 3 GPR85 mutations detected and family trees of the
patients with each base substitution. (a) M152T in GPR85 of
patient MR38 and his family member. (b) V221L in GPR85 of patient
Aut59 and his family member. NA, not available. (c) The position of
two mutations, M152T and V221L, in the human GPR85 molecule.
Arrows indicate the position of M152T (red) and V221L (yellow).
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ER accumulation of GPR85 was observed in 43% of cells
with the M152T mutation and 45% of cells with the V221L
mutation, but in only 17% of cells with normal GPR85
(Figure 4b).
We examined the co-localization of wild-type or mu-
tated GPR85 (M152T, V221L) with PSD-95 in C2C5 cells.
Wild-type GPR85, but not GPR85-deltaC, co-localized
with PSD-95 (Figure 5). In contrast to wild-type GPR85,
some of the mutated GPR85 did not co-localize with PSD-
95 (Figure 5).
Cells that expressed the mutated GPR85 protein also ex-
hibited ER stress markers, including CHOP up-regulation
(Figure 6a, b), eIF2α phosphorylation, and activated
caspase-3 (associated with apoptosis; Figure 6b). Thus,
the mutated GPR85 localized to the ER and induced ER
stress.
We examined the influence of GPR85 mutants on the
morphology of murine hippocampal neurons. Cultured
embryonic hippocampal neurons were transfected with
wild-type or mutant GPR85 and allowed to develop for
2 days in vitro. The neurons were then classified into
three categories based on dendrite length by immuno-
staining with MAP2, a dendritic marker: long dendrites
(>1,000 μm), short dendrites (<1,000 μm), and no den-
drites (<100 μm) (Figure 7 and Table 2). We found that
neurons expressing mutated GPR85 (M152T, V221L)
had shorter dendrites than neurons expressing wild-typeGPR85. Furthermore, neurons expressing GPR85 mutants
exhibited the decreased numbers of the dendritic branching
points [see Additional file 3: Figure S2].
We also examined the localization of wild-type and
mutated GPR85 on the dendrites of neurons. The wild-
type GPR85 punctate stainings co-localized with PSD-95,
a postsynaptic marker, on the dendrites and in the soma,
but less mutated GPR85 (M152T, V221L) punctate stain-
ings were detected on the dendrites, and some of them
did not co-localize with PSD-95 (Figure 8 and Additional
file 4: Figure S3).
Discussion
Mutations in GPR85 and ASD
The primary amino acid sequence of Gpr85 is identical in
human, monkey, rat, and mouse species [16,19]. There-
fore, the M152 and V221 amino acids are conserved
among all vertebrates. We found the M152T or the V221L
substitution in the GPR85 gene of 72 Japanese ASD pa-
tients and not in the 189 Caucasian ASD patients or in
the 632 control Japanese samples (Table 1). The frequency
Figure 4 The accumulation of the mutated GPR85 (M152T) and GPR85 (V221L) in C2C5 cells. (a) Intracellular accumulates of wild-type and
the two mutated GPR85. Green, full-length GPR85 (wild-type or mutants)-Myc-His; blue, Hoechst. (b) Percentages of cells showing accumulates
were determined by counting cells expressing wild-type and mutated GPR85 at 28 h after transfection. Scale bars, 25 μm.
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ASD seems to be quite similar to that of the mutation in
other genes related to ASD. For instance, the frequency of
SHANK3 mutation is in up to 2% to 3% of individuals with
ASD [26]. Moreover, T1033C (M152T) and G1239T
(V221L) mutations were not associated with any polymor-
phisms or SNPs, suggesting that the M152T or V221L mu-
tations were likely to be associated with ASD pathogenesis.
The M152T and V221L mutations were also detected
in each patient’s asymptomatic mother. We previously
observed this inheritance pattern, in which the ASD-
associated variant allele appears in an asymptomatic
mother and in her symptomatic male offspring, in our
previous study on MBD1 and other ASD-associated gene
variants [27]. These findings, and the higher prevalence
of ASD in males than in females, suggest that some
unknown protective mechanism might be present in
females that carry ASD-associated genes [27]. Other
studies of pedigrees that harbor mutations in SHANK3,
CNTNAP2, MECP2, MBD1, or CADM1 have also re-
ported that unaffected parents of either gender can carry
an ASD-associated mutation [2-4,27,28]. The fact that
ASD-related genotypes can be inherited from nonsymp-
tomatic mothers or fathers supports the theory thatFigure 5 Co-localization of the wild-type and mutated GPR85 and PSD
or GPR85(V221L), and PSD-95 was examined in C2C5 cells at 28 h after tran
green, PSD-95-GFP; some of the GPR85-deltaC, GPR85(M152T), GPR85(V221
aggregates of GPR85; closed arrowheads, GPR85 of co-localized with PSD-9
or GPR85, respectively. Scale bar, 20 μm. PSD, postsynaptic density protein.ASD mutations are dominantly transmitted, with low
penetrance in high-risk families [29].
Impaired NLGN-PSD95-GPR85 receptor complex and
dendrite formation
GPR-mediated signaling requires activation of the associ-
ated heterotrimeric G proteins. GPR85 is an orphan recep-
tor; thus, little is known about its physiological function
and signal transduction pathways. However, the M152T
and V221L mutations are located in GPR85 domains that
involve signal transduction and interaction with G proteins,
suggesting that these mutations cause deleterious loss-of-
function effects. Moreover, two software applications, the
Mutation Taster and ‘SIFT’, suggested that the M152T
amino acid change has a greater impact on protein function
than the V221L amino acid change.
NLGN and CADM1/CNTNAP2 interact with PSD-95
and MUPP1 via their PDZ-binding sequences, respect-
ively [24,30]. Mutations in these genes have been found
in ASD patients [1,3,4], suggesting that the impaired
function of these two distinct complexes is associated
with the pathogenesis of ASD. GPR85-C was associated
with both PSD-95 and NLGN in the brain (Figure 1).
Similar to NLGN, GPR85-C interacted with PSD-95-95. Co-localization of wild-type GPR85, GPR85-deltaC, GPR85(M152T)
sfection. Red, FLAG-Full-length GPR85 (wild-type, deltaC, or mutants);
L) did not co-localize with PSD-95. Area enclosed by broken lines,
5; open arrowheads, GPR85 or PSD-95 not colocalized with PSD-95
Figure 6 The mutated GPR85-molecule-induced ER stress in C2C5 cells. (a) Up-regulation of CHOP protein induced by the wild-type and the
mutated GPR85. (b) Detection of activation of ER stress markers, CHOP and eIF2α phosphorylation, and activation of caspase-3 by immunostaining
(upper panel) and percentages of their positive cells (lower panel). Green, GPR85; red, Chop and eIF2α phosphorylation (p-eIF2α) at 28 h after transfection
and activated caspase-3 at 32 h after transfection; blue, Hoechst. Scale bar, 20 μm. The percentage of the cells positive for CHOP, p-eIF2α, and activated
caspase-3 in the cells expressing wild-type and the two mutated GPR85. Error bars indicate standard error of the mean (*P< 0.05, **P< 0.01).
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MUPP1 (Figures 1 and 2). Furthermore, GPR85-C inter-
acted with PSD-95 via PDZ1 (Figure 2), whereas NLGN
binds PSD-95 via PDZ3. Therefore, GPR85 likely forms
a complex with NLGN through a different PDZ domain
of PSD-95.
In contrast to wild-type GPR85, some of the mutated
GPR85 as well as GPR85-deltaC did not co-localize with
PSD-95 in C2C5 cells and on the dendrites of neurons
(Figures 5 and 8), suggesting that mutated GPR85 inter-
acted more weakly with PSD-95 than wild-type GPR85,
although the missense mutation is not located in the
PDZ-binding sequence, which is necessary for interaction
with PSD-95. Mutated GPR85-deltaC or GPR85-deltaC as
well as the mutated GPR85 induced CHOP up-regulation
[see Additional file 5: Figure S4], suggesting that, in
addition to mutations themselves, weak interaction withFigure 7 Morphologies of dendrites of neurons expressing wild-type an
expressing the wild-type and the mutated GPR85. Isolated hippocampal neur
and mutated GPR85 (M152T or V221L) at DIV 7 and cultured and immunostai
bar, 50 μm. (b) Percentages of cells with long dendrites (1,000 μm). Error barsPSD-95 causes accumulation of mutated GPR85 in the
ER, resulting in the ER stress.
Compared to the neurons expressing wild-type GPR85,
the neurons expressing mutated GPR85 exhibited shorter
dendrites (Figure 7), the decreased number of GPR85
puncta, and an altered distribution of the mutated GPR85
on dendrites (Figure 8). These results suggest that the
GPR85 mutations cause a trafficking defect due to a lack
of interaction with PSD-95, resulting in impaired function
of the NLGN-PSD-95-GPR85 complex on the dendrites.
However, impaired dendrite formation or synaptic forma-
tion has not been observed in the brain of Gpr85-deficient
mice [18], suggesting that loss of function alone does not
affect the physiological function of neurons. Mutated forms
of GPR85 accumulated preferentially in the cells (Figures 5
and 6), suggesting that these mutations cause not only loss
of function, but also the accumulation of mutated GPR85d mutated GPR85. (a) Immunostaining of hippocampal neurons (DIV 9)
ons from mice embryos (E18) were transfected with His-tagged wild-type
ned with anti-His (red) and MAP2 (green) at DIV 9. Hoechst, blue. Scale
indicate standard error of the mean (**P < 0.01).
Table 2 Percentages of the neurons expressing three
types of dendrites in the neurons expressing GPR85
Typesa (9 DIVb) Wild-type M152T V221L
Neurons with long
dendrites, >1,000 μm
63.5 ± 9.0% 9.2 ± 4.8% 15.9 ± 7.0%
Neurons with short
dendrites, <1,000 μm
31.7 ± 4.9% 13.5 ± 5.1% 20.5 ± 4.8%
Neuron with no
dendrites, <100 μm
4.8 ± 1.6% 77.3 ± 4.6% 63.6 ± 4.5%
aTotal dendritic length/cell; bDIV = days in vitro.
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ing (Figure 8) and impaired dendrite formation (Figure 7).
Blocked dendrite formation may cause the complex impair-
ments in synaptic function that have been observed in pa-
tients with ASD who harbor GPR85 mutations. This
hypothesis will be studied in future in vitro culture experi-
ments and using Gpr85(M152T) knock-in mice.
Common molecular target for ASD and schizophrenia
Impaired synaptic functions are shared with other psy-
chiatric disorders including schizophrenia. Some of the
mutations of the genes related to ASD, including
NRXN1, NRXN2, NLGN2, NLGN4, SHANK3, and Syn-
GAP, have been also found in the schizophrenia patients
[10-13]; for instance, two de novo mutations (R1117X
and R536W) were identified in the SHANK3 gene of two
families of schizophrenia [13]. GPR85 is a risk factor for
schizophrenia, suggesting that GPR85 could be related
to the molecular pathogenesis of not only ASD but also
schizophrenia via interaction with PSD-95 or SAP102.
Thus, the putative ligand of GPR85 and its signaling
pathways may be a common molecular target for ASDFigure 8 Co-localization of wild-type GPR85 or GPR85 mutants
and PSD-95 in neurons. Co-localization of wild-type GPR85, GPR85
(M152T) or GPR85(V221L), and PSD-95 was examined in hippocampal
neurons (DIV 9) at 2 days after transfection. Red, wild-type GPR85
and GPR85 mutants (M152T and V221L)-Myc-His; green, PSD-95-GFP.
Scale bars, 20 μm. Closed arrowheads, punctum of GPR85 co-localized
with PSD-95 at synapse; open arrowheads, punctum of GPR85 not
co-localized with PSD-95 at synapse. PSD, postsynaptic density protein.and schizophrenia as described in [10-15]. We will investi-
gate our hypothesis regarding the molecular pathogenesis
of ASD and mutated GPR85 in future studies that employ
Gpr85 (M152T) knock-in mice.
Conclusions
GPR85 interacted with PSD-95, associating with NLGN
related to ASD. Two independent GPR85 mutations,
T1033C (M152T) and G1239T (V221L), were found in
male autism patients from Japanese families. Mutated
GPR85 preferentially accumulated, causing ER stress and
disturbing the dendrite formation of hippocampal neu-
rons. Thus, mutated GPR85 could be associated with the
molecular pathogenesis of ASD, and GPR85 may be a
common molecular target for ASD and schizophrenia.
Additional files
Additional file 1: Table S1. Primers sequences of GPR85. These primers
(5 sets) were used for the nucleotide sequence analysis of GPR85. The
fragment length and annealing temperature for each PCR product are
indicated in this Table S1.
Additional file 2: Figure S1. The localization of endogenous GPR85 in
C2C5 cells. The GPR85 protein was detected by immunohistochemical
staining methods using rabbit anti-GPR85. GPR85 was mainly localized in
ER (rough ER). Scale bar indicates 20 μm.
Additional file 3: Figure S2. Sholl analysis of hippocampal neurons
transfected wild-type and mutated GPR85. In contrast to wild-type GPR85,
the mutated GPR85 exhibit a decreased level of dendritic complexity in DIV 9.
The x-axis indicates distance from the origin; the y-axis indicates the number
of dendritic intersections. Error bars indicate SEM. Neurons transfected were
wild-type GPR85 (n= 16), GPR85 (M152T) (n= 16), and GPR85 (V221L) (n= 17),
and they were examined by Sholl analysis, which was performed using the
NIH ImageJ (Sholl Analysis Plugin). Analysis parameters were as follows:
starting radius, 1 μm; ending radius, 75 μm; radius step size, 2 μm;
radius span, 1 μm; span type, median.
Additional file 4: Figure S3. The localization of endogenous GPR85
in hippocampus neurons. The GPR85 and PSD-95 was detected by
immunohistochemical staining methods using rabbit anti-GPR85 (red)
and mouse anti-PSD-95 (green). Hoechst, blue. In the dendrites, GPR85
was mostly co-localized with PSD-95 at spines. Scale bar indicates 50 μm.
Additional file 5: Figure S4. The effect of PDZ-binding domain on the
localization in C2C5 cells and ER stress. Localization of FLAG-full-length
GPR85-deltaC, GPR85(M152T)-deltaC, and GPR85(V221L)-deltaC protein
were detected by immunohistochemical staining using mouse or rabbit
anti-FLAG. They did not co-localize (arrows) with PSD-95-GFP and induced
ER stress, detected by mouse anti-CHOP. Scale bars indicate 20 μm.
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